
Some Africans have long seen a big belly as a sign of wealth. It's killing them
In
Kenya
, overweight politicians are often called Boss or Mkubwa — Swahili for 'big man' — by constituents, with their girth symbolizing prosperity.
Younger politicians, including the governors of Nairobi and Mombasa, have begun speaking publicly about weight loss. Obesity contributes to non-communicable diseases such as diabetes, which have become Kenya's leading cause of death. The health ministry says they are responsible for 39% of fatalities annually.
In a country where the government has said almost a third of the population is still unable to fulfill food needs, 13% adults are obese, according to the 2025 World Obesity Atlas. The contrast highlights the country's growing inequality and the popularity of fast and processed foods by those with rising incomes.
Perceptions about obesity can affect financial and other decisions. In neighboring Uganda, microfinance institutions vetted loan applicants based on their weight, and those overweight were considered more able to repay loans, according to a study published by the American Economic Review in 2023.
'Most people feel like when I start making money, I have to look like the money itself by being fat or obese,' said Kenyan nutritionist Felix Okoth. 'They however don't realize that they are predisposing themselves to these lifestyle conditions such as diabetes and hypertension.'
The World Health Organization's Africa director has called the rising trend a 'ticking time bomb' for the continent with the world's youngest and fastest growing population.
Some are trying to change the conversation around weight. A former senator in Kenya, Cleophas Malala, has described how a 15-hour flight to the U.S. left him in pain and how doctors advised him to reduce.
From a starting weight of 138 kilograms (304 pounds), he embarked on a non-solid diet for 90 days. Though he didn't disclose his current weight, before-and-after photos show him noticeably slimmer.
'My colleagues in parliament were mad that I left the 'club' after I lost weight,' the 39-year-old has said.
Stephen Ogweno, who had childhood obesity and later became a public health advocate, said most Kenyan legislators don't see the issue as a problem.
'These discussions are held in parliament where most MPs have big bellies, and so admitting that it concerns them, too, would be a good place to start,' he said,
Kenyan President
William Ruto
has spoken publicly about the need to be fit for work. He had to reassure Kenyans in 2023 that he was okay after online speculation about his health following weight loss.
'I decided to cut it down because the task ahead was not easy,' he told journalists.
Increasing incomes, proliferation of fast-food outlets in urban areas, sedentary lifestyles and lack of infrastructure that promotes physical activity have been named as probable causes of rising obesity in developing countries.
'We need to make sure that when we move away from lack of food, we are not going to the wrong food groups,' said a Kampala-based doctor, Miriam Laker Oketta.
Public health campaigns will help demystify the perception that weight is an indication of wealth, said Caroline Kirui, the Africa director for Project ECHO, an information-sharing platform for healthcare workers.
Gyms, weight loss drugs and surgeries are being increasingly advertised in Kenya.
But approaches such as the Ozempic weight-loss drug have left some users like Caroline Havi dissatisfied. She said she turned to a one-meal-a-day diet instead and hopes to eventually reduce her weight from 105 kilograms to 70 'without spending so much.'
In South Africa, obesity-related deaths due to non-communicable diseases have surpassed HIV-related deaths, according to the WHO. The 2025 World Obesity Atlas said 32% of South Africa's adults are obese.
The perception that weight is a symbol of wealth is slowly changing, said Rebone Ntsie, nutrition director at the National Department of Health.
'There are those who still see it like that, but people are also seeing the dangers and its no longer celebrated as a sign of dignity, beauty, respect, social status,' she said.
___
Associated Press journalist Michelle Gumede contributed from Johannesburg, South Africa.
___
For more on Africa and development:
https://apnews.com/hub/africa-pulse
The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's
standards
for working with philanthropies, a list of supporters and funded coverage areas at
AP.org
.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
3 hours ago
- Yahoo
HealthStream: Q2 Earnings Snapshot
NASHVILLE, Tenn. (AP) — NASHVILLE, Tenn. (AP) — HealthStream Inc. (HSTM) on Monday reported net income of $5.4 million in its second quarter. On a per-share basis, the Nashville, Tennessee-based company said it had profit of 18 cents. The provider of internet-based educational and training content for health care professionals posted revenue of $74.4 million in the period. HealthStream expects full-year revenue in the range of $297.5 million to $303.5 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on HSTM at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


USA Today
4 hours ago
- USA Today
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa. This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses. This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation. The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate's potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic. 'This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI's sponsorship, ReiThera's GRAd technology, the Ragon Institute's innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.' said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust. 'This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV,' said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI. The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions. 'We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality,' said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard. Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions. 'We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership,' said Stefano Colloca, CEO and co-Founder of ReiThera. 'This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions.' Principal Investigators Leading Clinical Trial Sites: Tariro Makadzange, Mutala Trust Theodorah Rirhandzu Ndzhukule, DTHF Limakatso Lebina, AHRI About IAVI IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at IAVI media contact Heather Teixeira hteixeira@ About Mutala Trust Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study. Mutala Trustmedia contact coms@ About ReiThera Srl. ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine. ReiThera media contact communication@ About the Ragon Institute of Mass General Brigham, MIT, and Harvard The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit Ragon Institutemedia contact ragoncommunications@ SOURCE: IAVI View the original press release on ACCESS Newswire


New York Post
4 hours ago
- New York Post
Canadian wildfires spark NY air-quality alert: ‘Can pose serious health risks'
Canadian wildfires may be posing 'serious health risks'' to people in New York — prompting an air-quality alert for the state through Monday and a warning for some regions into Tuesday. The metro area's current ailing air quality and hazy skies are hampering the five boroughs, Long Island, Hudson Valley, Adirondacks, eastern Lake Ontario and Central and Western New York regions, according to an alert issued Monday by Gov. Kathy Hochul. Canadian wildfires cloak Manhattan in haze last month. Luiz C. Ribeiro for New York Post Advertisement Pollution from fine particulate matter fueled by the wildfires is expected to push the local Air Quality Index past 100, meaning it will be unhealthy for sensitive groups, including children, older adults and people with heart or lung conditions. In some areas, the index could go above 150 momentarily. The tiny particles can cause eye, nose, and throat irritation along with coughing, sneezing and shortness of breath. They can also worsen asthma and heart disease. Advertisement 'New York continues to track air quality conditions across the state, and people in certain areas may notice visible smoke throughout the day,' Hochul said in a statement. The advisory remains in effect through 11:59 p.m. Monday, but weather patterns are anticipated to bring more spikes in smoke in certain regions across the state Tuesday. Wildfires destroy scores of acres in British Columbia. AP Officials urged everyone in sensitive groups to check their local Air Quality Index and take precautions, including limiting outdoor activity. Advertisement 'Poor air quality can pose serious health risks — especially for those with heart conditions, lung diseases, such as asthma, young children, those over 65 years old, and pregnant individuals,' New York Health Commissioner Dr. James McDonald said in a statement. 'To reduce exposure, limit strenuous activity outdoors.' The smoky situation is just the latest to cloud city skies this year. Multiple alerts were issued in June when ozone pollution and wildfire haze from Canada triggered warnings across the tri-state area. Advertisement More than 700 active wildfires are currently blazing across Canada, with roughly two-thirds of them still out of control, according to the Canadian Interagency Forest Fire Center.